These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35224054)

  • 21. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
    Hundemer GL; Talarico R; Tangri N; Leon SJ; Bota SE; Rhodes E; Knoll GA; Sood MM
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):365-373. PubMed ID: 33608262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
    Chan EY; Ma AL; Tullus K
    Pediatr Nephrol; 2021 Jul; 36(7):1751-1764. PubMed ID: 33057769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperkalemia in patients with chronic renal failure.
    Seliger SL
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii12-iii18. PubMed ID: 31800076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-Benefit Balance of Renin-Angiotensin-Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia.
    Kohsaka S; Okami S; Morita N; Yajima T
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
    Epstein M; Reaven NL; Funk SE; McGaughey KJ; Oestreicher N; Knispel J
    Am J Manag Care; 2015 Sep; 21(11 Suppl):S212-20. PubMed ID: 26619183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials.
    Haller H; Bianchi S; McCafferty K; Arthur S; Quinn CM; Budden J; Weir MR
    Kidney360; 2022 Dec; 3(12):2019-2026. PubMed ID: 36591361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
    Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
    Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
    BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study).
    Bjune T; Bøe TB; Kjellevold SA; Heldal K; Abedini S
    Int J Nephrol Renovasc Dis; 2023; 16():73-82. PubMed ID: 36960344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
    Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
    Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors.
    Fravel MA; Meaney CJ; Noureddine L
    Curr Hypertens Rep; 2023 Nov; 25(11):395-404. PubMed ID: 37747576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.
    Bushinsky DA; Williams GH; Pitt B; Weir MR; Freeman MW; Garza D; Stasiv Y; Li E; Berman L; Bakris GL
    Kidney Int; 2015 Dec; 88(6):1427-1433. PubMed ID: 26376130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
    Georgianos PI; Agarwal R
    Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperkalemia and risk of chronic kidney disease progression: A propensity score matched analysis.
    Agiro A; Cook E; Mu F; Greatsinger A; Chen J; Zhao A; Louden E; Colman E; Desai P; Chertow GM
    Kidney360; 2024 Aug; ():. PubMed ID: 39120948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial.
    Mårup FH; Peters CD; Nielsen SF; Nygaard L; Madsen B; Mose FH; Birn H
    Kidney Int Rep; 2024 Aug; 9(8):2399-2409. PubMed ID: 39156169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
    Leon SJ; Carrero JJ
    Curr Opin Nephrol Hypertens; 2023 May; 32(3):290-296. PubMed ID: 36811640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28485202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.